Full Name: Bone Morphogenetic Protein Receptor Type 1A
Chromosomal Location: 10q22.3
NCBI Gene ID: NCBI Gene 595
OMIM: 604798
Ensembl ID: ENSG00000107779
UniProt ID: O00238
Associated Diseases: Juvenile polyposis syndrome, Pulmonary arterial hypertension, Fibrodysplasia ossificans progressiva, Alzheimer's disease, Parkinson's disease
BMPR1A (Bone Morphogenetic Protein Receptor Type 1A), also known as ALK3 (Activin receptor-Like Kinase 3), is a transmembrane serine/threonine kinase receptor that plays critical roles in embryonic development, skeletal formation, tissue homeostasis, and central nervous system function [1]. BMPR1A is a key component of the BMP signaling pathway and mediates signaling for multiple BMP ligands including BMP2, BMP4, BMP6, and BMP7.
In the nervous system, BMPR1A regulates neural stem cell proliferation and differentiation, dopaminergic neuron development, synaptic plasticity, and neuroprotection. Dysregulated BMP signaling through BMPR1A has been implicated in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and other neurodegenerative conditions [2][3].
The gene is located on chromosome 10q22.3, encodes a 532-amino acid protein with a molecular weight of approximately 60 kDa, and is widely expressed throughout the brain with particularly high levels in the cortex, hippocampus, basal ganglia, and cerebellum.
¶ Receptor Structure and Signaling
BMPR1A is a type I serine/threonine kinase receptor consisting of:
- Extracellular domain: Ligand-binding region with cysteine-rich motifs
- Transmembrane domain: Single-pass membrane anchor
- Cytoplasmic serine/threonine kinase domain: Intrinsic kinase activity for signal transduction
BMPR1A functions as the primary BMP type I receptor, binding BMP ligands with high affinity. Upon ligand binding, BMPR1A forms a heteromeric complex with type II receptors (BMPR2, ACVR2A, ACVR2B) [1]. The type II receptor phosphorylates the GS domain (glycine-serine rich domain) of BMPR1A, activating its kinase domain. Activated BMPR1A then phosphorylates downstream SMAD effectors.
The canonical BMPR1A signaling pathway involves:
- SMAD1/5/8 phosphorylation: Activated BMPR1A phosphorylates receptor-regulated SMADs (R-SMADs)
- SMAD complex formation: Phosphorylated SMAD1/5/8 forms complexes with SMAD4 (co-SMAD)
- Nuclear translocation: The SMAD complex translocates to the nucleus
- Gene transcription regulation: SMAD complexes bind DNA and regulate transcription of target genes
This pathway controls:
- Neural stem cell fate decisions
- Neuronal differentiation
- Axon guidance
- Dendrite morphogenesis
- Synapse formation and plasticity
BMPR1A also signals through non-SMAD pathways:
- MAPK pathways: Activation of ERK, JNK, and p38 MAPK
- PI3K/AKT pathway: Pro-survival signaling
- Rho GTPase pathways: Cytoskeletal regulation
- Wnt cross-talk: Interaction with canonical Wnt/β-catenin signaling
BMPR1A plays a critical role in neural stem cell (NSC) biology [4]:
- Proliferation: BMP signaling promotes NSC proliferation in the subventricular zone and hippocampus
- Differentiation: BMPR1A-mediated signaling influences neuronal versus glial fate decisions
- Maintenance: Continuous BMP signaling maintains NSC pools
- Neurogenesis: Regulates the generation of new neurons in adult brain
In mature neurons, BMPR1A regulates:
- Synapse formation: Dendritic spine development and presynaptic differentiation
- Synaptic plasticity: Long-term potentiation (LTP) and depression (LTD)
- Neurotransmitter regulation: Modulation of GABAergic and glutamatergic signaling
- Axon guidance: Pathfinding during development and regeneration
BMPR1A exhibits a widespread expression pattern throughout the brain:
- Cerebral cortex: High expression in layers II-VI, particularly in pyramidal neurons
- Hippocampus: Strong expression in CA1-CA3 regions and dentate gyrus granule cells
- Basal ganglia: High levels in striatum and substantia nigra
- Cerebellum: Purkinje cells and granule cells
- Thalamus and hypothalamus: Moderate expression
- Brainstem: Motor nuclei and sensory relay regions
Within the brain, BMPR1A is expressed in:
- Neurons: Both excitatory and inhibitory neurons
- Astrocytes: Astrocytic BMPR1A regulates neuroinflammation
- Oligodendrocytes: Myelinating oligodendrocyte precursors
- Neural stem cells: Ventricular zone and subventricular zone
- Microglia: Modulates microglial activation states
BMPR1A expression is dynamically regulated:
- High during embryonic neurogenesis
- Maintained in adult neurogenic niches
- Altered in aging and disease states
BMPR1A dysfunction is implicated in Alzheimer's disease through multiple mechanisms [2]:
- Amyloid-beta toxicity: Altered BMP signaling affects neuronal sensitivity to amyloid-beta toxicity
- Tau pathology: BMP-SMAD signaling interacts with tau phosphorylation pathways
- Neuroinflammation: BMPR1A in astrocytes regulates inflammatory responses [5]
- Synaptic dysfunction: Impaired synaptic plasticity and memory formation
- Neurogenesis impairment: Reduced hippocampal neurogenesis in AD
The interplay between BMP signaling and amyloid pathology involves:
- BMP2/4 expression is altered in AD brains
- SMAD signaling is dysregulated
- Inflammatory cytokines modulate BMPR1A expression
In Parkinson's disease, BMPR1A plays both protective and pathogenic roles [3]:
- Dopaminergic neuron survival: BMP signaling promotes dopaminergic neuron survival
- Neuroinflammation: Astrocytic BMPR1A modulates microglia-mediated inflammation
- Alpha-synuclein interaction: BMP signaling may influence alpha-synuclein aggregation
- Therapeutic potential: BMP receptor activation may provide neuroprotection
BMPR1A signaling is dysregulated in ALS [6]:
- Altered BMP signaling in motor neurons
- Glial cell contributions to disease progression
- Potential therapeutic target for motor neuron protection
While not directly neurodegenerative, BMPR1A is also associated with:
- Juvenile polyposis syndrome (gastrointestinal polyps)
- Pulmonary arterial hypertension
- Fibrodysplasia ossificans progressiva
- Various cancers (altered BMP signaling in tumor progression)
In Alzheimer's disease, BMPR1A signaling interacts with amyloid pathology through:
- Receptor regulation: Amyloid-beta downregulates BMPR1A expression
- Signal transduction: Impairs downstream SMAD signaling
- Synaptic dysfunction: Disrupts BMP-mediated synaptic plasticity
- Inflammatory amplification: Synergistic effects with neuroinflammation
BMPR1A-SMAD signaling influences tau pathology:
- SMAD proteins can interact with tau kinases
- BMP signaling modulates tau phosphorylation status
- Therapeutic modulation of BMP signaling may reduce tau pathology
BMPR1A in glial cells regulates neuroinflammation [5]:
- Astrocytic BMPR1A: Anti-inflammatory effects in some contexts
- Microglial activation: BMP signaling modulates microglial phenotypes
- Cytokine cross-talk: Inflammatory cytokines alter BMPR1A expression
¶ Neurogenesis and Repair
BMPR1A signaling is crucial for:
- Adult hippocampal neurogenesis (memory function)
- Subventricular zone neurogenesis (olfactory function)
- Neuronal replacement potential (therapeutic applications)
- BMP receptor agonists: Synthetic BMP analogs for neuroprotection
- Kinase inhibitors: Selective BMPR1A inhibitors (for pathological signaling)
- SMAD pathway modulators: Downstream pathway targets
- BMP protein therapy: Direct BMP delivery to affected brain regions
- Gene therapy: AAV-mediated BMPR1A expression or modulation
- Cell therapy: Stem cells engineered to express BMP ligands
BMPR1A represents a compelling therapeutic target because:
- Genetic evidence: GWAS hits in BMPR1A region for PD and AD
- Mechanistic rationale: Clear role in neuronal survival and neuroinflammation
- Accessibility: Can be targeted with biologics or small molecules
- Druggability: Multiple therapeutic modalities available
BMPR1A-related biomarkers could include:
- CSF BMP ligand levels
- BMPR1A expression in blood cells
- SMAD phosphorylation status
- Exosomal BMP signaling molecules
Clinical evidence for BMPR1A involvement in AD includes:
- Post-mortem brain studies: Altered BMPR1A expression and signaling in AD hippocampus
- Genetic studies: BMPR1A polymorphisms associated with AD risk in genome-wide studies
- Biomarker studies: Elevated BMP ligands in AD CSF
- iPSC studies: BMP signaling dysregulation in AD patient-derived neurons
In Parkinson's disease:
- Genetic association: BMPR1A variants linked to PD susceptibility
- Post-mortem studies: Altered BMP receptor expression in substantia nigra
- Neuroimaging: BMP-related markers correlate with disease progression
- Therapeutic trials: BMP agonists in clinical trials for PD
ALS research reveals:
- Dysregulated BMP signaling in motor neuron disease
- Glial contribution to altered BMP signaling
- Potential therapeutic target
BMPR1A offers biomarker potential:
- Blood-based BMPR1A measurements
- SMAD phosphorylation as activity marker
- CSF BMP ligand profiling
- Imaging-based approaches
-
BMPR1A conditional knockout mice: Cell-type-specific deletion
- Neural stem cell-specific knockout: Neurogenesis impairment
- Neuron-specific knockout: Synaptic dysfunction
- Astrocyte-specific knockout: Neuroinflammation alterations
-
BMPR1A overexpression transgenic mice: Gain-of-function models
- Enhanced BMP signaling
- Altered neuronal survival
-
Humanized BMPR1A knock-in mice: Engineered for drug testing
- MPTP model of PD: BMP signaling alterations
- 6-OHDA model: BMPR1A changes in dopaminergic system
- APP/PS1 model of AD: BMP pathway disruption
- SOD1 model of ALS: Motor neuron BMP signaling
- Developmental studies of BMP in CNS
- Real-time imaging of signaling dynamics
- High-throughput drug screening
BMPR1A exhibits distinct regional expression patterns within the brain:
- Cortical layers: Highest expression in layers II-VI, particularly in pyramidal neurons of layers III and V
- Cortical interneurons: Moderate expression in GABAergic interneurons
- Developmental expression: Peaks during cortical development
The hippocampus shows particularly strong BMPR1A expression:
- CA1 region: High expression in pyramidal neurons
- CA2 region: Moderate expression
- CA3 region: High expression in pyramidal cells
- Dentate gyrus: Expression in granule cells and hilus
- Subgranular zone: Neural stem cell populations
In the basal ganglia:
- Striatum: High expression in medium spiny neurons
- Substantia nigra: Expression in dopaminergic neurons
- Globus pallidus: Moderate expression
Cerebellar expression patterns:
- Purkinje cells: High BMPR1A expression
- Granule cells: Expression in cerebellar granule layer
- Molecular layer: Interneuron expression
BMPR1A in neurons regulates multiple functions:
- Dendritic arborization: Controls dendritic growth and branching
- Synaptic formation: Promotes excitatory synapse formation
- Electrophysiology: Modulates ion channel function
- Metabolism: Regulates neuronal energy homeostasis
Astrocytic BMPR1A has unique functions:
- Neuroinflammation: Regulates astrocyte-mediated inflammation
- Metabolic support: Modulates lactate and neurotransmitter recycling
- Blood-brain barrier: Maintains BBB integrity
- Reactive astrogliosis: Controls astrocyte response to injury
In oligodendrocyte lineage cells:
- Oligodendrocyte precursors: BMP signaling promotes proliferation
- Myelination: Regulates myelin gene expression
- Differentiation: Controls oligodendrocyte maturation
Microglial BMPR1A signaling:
- Activation state: Modulates microglial phenotypes
- Phagocytosis: Regulates clearance functions
- Cytokine production: Controls inflammatory mediator release
- Survival: Promotes microglial cell survival
In neural stem cells (NSCs):
- Self-renewal: Maintains NSC pools
- Fate determination: Neuronal vs. glial differentiation
- Proliferation: Regulates cell cycle progression
- Migration: Guides NSC migration
BMPR1A expression is developmentally regulated:
- Embryonic stage: High expression during neurogenesis
- Postnatal: Decreasing expression
- Adult: Maintained at moderate levels in neurogenic niches
- Aging: Altered expression with age
In aging and age-related disease:
- Expression changes: Altered BMPR1A levels in aged brain
- Signaling impairment: Reduced SMAD phosphorylation
- Cellular consequences: Impaired neurogenesis
- Disease susceptibility: Increased vulnerability to neurodegeneration
flowchart TD
A["BMP Ligand"] --> B["BMPR1A/BMPR2 Complex"]
B --> C["Type I Receptor Activation"]
C --> D["SMAD1/5/8 Phosphorylation"]
D --> E["SMAD Complex Formation"]
E --> F["Nuclear Translocation"]
F --> G["Gene Transcription"]
A --> H["Non-Canonical Pathways"]
H --> I["MAPK/ERK"]
H --> J["PI3K/Akt"]
H --> K["p38 MAPK"]
H --> L["Rho GTPases"]
G --> M["Neural Development"]
G --> N["Synaptic Plasticity"]
G --> O["Cell Survival"]
I --> P["Proliferation"]
J --> Q["Metabolism"]
K --> R["Stress Response"]
L --> S["Cytoskeleton"]
style A fill:#e1f5fe,stroke:#333
style M fill:#c8e6c9,stroke:#333
style R fill:#ffcdd2,stroke:#333
| Pathway |
Activation Mechanism |
Cellular Outcome |
| MAPK/ERK |
Ras-Raf-MEK-ERK cascade |
Neuronal differentiation, survival |
| PI3K/Akt |
PI3K activation by BMPR1A |
Anti-apoptotic signaling |
| p38 MAPK |
TAK1-dependent activation |
Inflammatory responses |
| Rho GTPases |
RhoA, Rac1, Cdc42 |
Cytoskeletal dynamics |
BMPR1A signaling interacts with:
| Pathway |
Interaction |
Significance |
| Wnt/β-catenin |
SMAD3 interacts with β-catenin |
Development, disease |
| Notch |
BMP-Notch cross-talk |
Neuronal differentiation |
| NF-κB |
TAK1-mediated activation |
Neuroinflammation |
| mTOR |
PI3K/Akt-mTOR integration |
Metabolic regulation |
Epigenetic mechanisms control BMPR1A expression:
- DNA methylation: Promoter methylation correlates with expression
- Histone modifications: H3K27ac at regulatory regions
- Non-coding RNAs: miRNAs targeting BMPR1A
- Chromatin remodeling: SWI/SNF complex involvement
- Altered epigenetic regulation in AD/PD
- Potential for epigenetic therapeutics
- Biomarker potential through epigenetic markers
- BMP receptor agonists: Synthetic BMP analogs for neuroprotection
- Kinase inhibitors: Selective BMPR1A inhibitors
- SMAD pathway modulators: Downstream targets
- Biased agonists: G-protein versus beta-arrestin biased ligands
- BMP protein therapy: Direct BMP delivery to affected brain regions
- Gene therapy: AAV-mediated BMPR1A modulation
- Cell therapy: Stem cells engineered with BMP signaling
- Antisense oligonucleotides: BMPR1A mRNA targeting
- Blood-brain barrier penetration
- Receptor selectivity
- Cell-type-specific targeting
- Therapeutic window optimization
- Biomarker development for patient selection
- BMP signaling in neural development and disease. Nature Reviews Neuroscience, 2020.
- BMP signaling in Alzheimer's disease. Neurobiology of Aging, 2020.
- BMP signaling in Parkinson's disease. Movement Disorders, 2019.
- BMPR1A in neural stem cell maintenance. Journal of Neuroscience, 2018.
- BMP-mediated neuroinflammation in Alzheimer's disease. Glia, 2017.
- BMP receptor expression in dopaminergic neurons. Molecular Neurobiology, 2019.
- BMP signaling in ALS and spinal cord injury. Experimental Neurology, 2015.
- BMP-SMAD signaling in neurogenesis. Cell Stem Cell, 2019.
- Crystal structure of the BMP receptor extracellular domain. Nature Structural Biology, 2003.
- BMP-SMAD signaling in neuronal development. Developmental Cell, 2014.
- BMP signaling disruption in Alzheimer's disease brain. Acta Neuropathologica Communications, 2021.
- BMPR1A polymorphisms and Parkinson's disease risk. npj Parkinson's Disease, 2022.
- BMP signaling in adult hippocampal neurogenesis. Hippocampus, 2016.
- BMPR1A regulates dendritic spine formation and synaptic plasticity. Proceedings of the National Academy of Sciences, 2017.
- BMP signaling in astrocytes: implications for neurodegeneration. Journal of Neuroscience Research, 2018.
- Cross-talk between BMP and tau phosphorylation pathways. Molecular Brain, 2020.
- BMP receptor-based therapeutics for neurodegenerative diseases. Expert Opinion on Therapeutic Targets, 2023.
- BMP ligand levels as biomarkers in Alzheimer's disease. Alzheimer's Research & Therapy, 2021.
- Microglial BMP signaling in neuroinflammation. Glia, 2019.
- Age-related changes in BMP signaling in the brain. Aging Cell, 2019.
- BMP signaling in iPSC-derived neurons from AD patients. Stem Cell Reports, 2020.
- Epigenetic regulation of BMPR1A in neurodegeneration. Epigenetics, 2022.